Founder Mark Kotter describes the science that has enabled bit.bio to design and manufacture virtually any cell type and characteristic from iPSCs

He explains how machine learning has allowed bit.bio to model which transcription factor combinations are needed to create a desired cell type. The company is now using this to create cells for research purposes and as therapeutics.